FDA Grants Fast Track Designation to Giredestrant for Early-Stage ER+/HER2- Breast Cancer Following ASCO lidERA Data

On June 2, 2026 — the final day of the ASCO Annual Meeting — the FDA granted Fast Track Designation to giredestrant (Roche/Genentech) for the treatment of Stage I–III ER-positive/HER2-negative early breast cancer, based on the ASCO 2026 presentation of the Phase 3 lidERA BC trial data showing a 30% reduction in invasive disease recurrence versus standard endocrine therapy. Fast Track designation facilitates more frequent interactions with the FDA during development and eligibility for priority review and rolling review, potentially accelerating giredestrant's path to approval. Giredestrant is an oral, nonsteroidal selective estrogen receptor degrader (SERD) taken once daily — the first oral SERD to demonstrate statistically significant superiority over standard aromatase inhibitor or tamoxifen therapy in the adjuvant early breast cancer setting. This designation follows earlier designations for giredestrant in metastatic breast cancer. Roche plans to submit a New Drug Application to FDA based on the lidERA data, with discussions with EMA also ongoing. Early ER+/HER2- breast cancer represents approximately 150,000 new patients per year in the US alone, making this a large and commercially significant indication. The FDA also approved Cavhanza (nilotinib orally disintegrating tablet) on June 2 for adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) — an innovative formulation enabling co-administration with proton pump inhibitors and H2 receptor antagonists that are incompatible with conventional nilotinib capsules due to food and drug interactions.